AFib care is rarely a single decision. Most patients are weighing medication, ablation, and now cellular therapy at the same time, often inside the same appointment. The standard tools have decades of clinical history behind them. Each is designed to manage a different consequence of the condition, and each carries a different set of trade offs that a patient and a cardiologist need to talk through together.

How AFib Is Treated Today

Modern AFib care is organized around three goals: control the rate, control the rhythm, and reduce the stroke risk that AFib creates. Most patients move through the toolbox in a sequence. Medication is usually the first step. Ablation is offered when medication is not enough. Surgery and pacemakers are reserved for the harder cases.

Each option below is built around one of those goals. They are not interchangeable, and they do not address the same layer of the condition.

Rate Control Medications

Rate control medication is usually the first step in AFib care. The goal is to slow the lower chambers of the heart so that a fast or irregular rhythm feels less intense and the patient can function on a normal day. Beta blockers such as metoprolol and rhythm calming calcium channel blockers such as diltiazem are the most common choices. Digoxin is sometimes added in older patients or in heart failure.

Rate control does not stop AFib. It changes how the heart responds to it. A patient on a rate control medication is still in atrial fibrillation, just at a slower and steadier pulse. The medication is taken daily, and most patients stay on it for years.

Side effects can include fatigue, low blood pressure, slow heart rate, and dizziness, especially when treatment first begins. The medications can also interact with other heart drugs, so dosing is usually adjusted carefully over the first weeks.

Rhythm Control Medications

Rhythm control medication tries to keep the heart in a normal rhythm rather than slow the response to a bad one. Common options include flecainide, propafenone, sotalol, dofetilide, dronedarone, and amiodarone. The choice depends on the patient's other medical conditions and on whether the heart shows structural changes.

Some of these medications require a short hospital stay to start safely so the doctor can watch the heart on a monitor. Others are started in the clinic with regular follow up. The goal is the same: keep the rhythm regular while the medication is in the patient's system.

Rhythm control medication tends to lose effectiveness over time as AFib progresses. Side effects vary by drug, and amiodarone in particular carries a longer list that can include effects on the lungs, thyroid, liver, and skin. Rhythm control is usually reviewed at every visit.

Anticoagulants

AFib raises the risk of stroke because blood that is not moving smoothly through the upper chambers of the heart can form clots. Anticoagulant medication thins the blood so those clots do not form, or do not form as easily. Warfarin was the standard for decades and is still used in specific situations. Direct oral anticoagulants such as apixaban, rivaroxaban, dabigatran, and edoxaban have become the more common choice for most patients.

Anticoagulants are usually taken daily, often for life once they are started. They reduce stroke risk in patients with AFib but do not change the rhythm itself. The trade off is bleeding risk. Cuts take longer to stop, bruises appear more easily, and any major bleeding event has to be managed quickly.

Stroke risk in AFib is calculated using a tool called the CHA2DS2 VASc score. The decision to start an anticoagulant, and which one to use, is built around that score and the patient's bleeding risk.

Cardioversion

Cardioversion is a procedure that resets the rhythm of the heart. In electrical cardioversion, the patient is sedated and a synchronized shock is delivered through pads on the chest. In chemical cardioversion, a medication is given that converts the rhythm. Bernard Lown described the modern electrical version in 1962, and it has been a standard tool in AFib care ever since.

Cardioversion is typically used when AFib is symptomatic and a return to normal rhythm is the goal. The procedure is short, often done as an outpatient, and the patient goes home the same day. Many patients eventually go back into AFib, sometimes within weeks and sometimes after years, which is why cardioversion is often paired with rhythm control medication or with ablation.

Catheter Ablation

Catheter ablation is a hospital procedure that targets the parts of the heart sending the abnormal signals. The patient is put to sleep, a thin tube is threaded through a vein up into the heart, and the tip is used to scar the tissue around the pulmonary veins with heat (radiofrequency) or cold (cryoablation). Newer pulsed field ablation systems use short electrical pulses to do the same job. Michel Haïssaguerre and colleagues established the role of the pulmonary veins in AFib in a 1998 New England Journal of Medicine paper, and that work is the foundation for the procedure as it is performed today.

Ablation is typically offered when medication has not controlled the rhythm or when the patient prefers a procedure to long term medication. Outcomes are best when AFib is paroxysmal, meaning it comes and goes, and the heart structure is otherwise healthy. Recurrence rates rise in patients with persistent AFib or with a more remodeled heart, and a meaningful share of patients need a second ablation.

Risks are uncommon but real. They include bleeding at the access site, fluid around the heart, damage to nearby tissue, and stroke. The procedure requires anesthesia and a recovery period, and most centers ask patients to stay on an anticoagulant for several months afterward.

Surgical Ablation and the Maze Procedure

Surgical ablation is a more involved version of the same idea, performed in the operating room. The Cox Maze procedure, developed by James Cox in 1987, uses a pattern of incisions or energy lines on the atrial wall to interrupt the abnormal signals at their source. Modern versions use radiofrequency or cryoablation rather than a scalpel and can sometimes be done through smaller incisions.

Surgical ablation is most often offered to patients who are already having heart surgery for another reason, such as valve repair or coronary bypass, and to patients with longstanding persistent AFib who have not responded to other treatments. Outcomes for rhythm control are strong in the right setting, but the procedure carries the risks and recovery time of cardiac surgery.

Pacemakers and AV Node Ablation

For patients in whom rhythm cannot be controlled and rate cannot be slowed, an option called AV node ablation with a pacemaker is sometimes used. The atrioventricular node, the electrical relay between the upper and lower chambers, is intentionally ablated, and a pacemaker is implanted to keep the lower chambers beating on a steady cadence. The atria continue to fibrillate, but the ventricles no longer respond to the chaos.

This option is typically reserved for patients who have run out of other choices. It commits the patient to a permanent pacemaker and to lifelong anticoagulation, since the atria are still in AFib.

Lifestyle and Risk Factor Care

Modern AFib guidelines place real weight on lifestyle and risk factor care alongside medication and procedures. Weight management, treatment of obstructive sleep apnea, blood pressure control, reduction or elimination of alcohol, regular physical activity, and management of diabetes are all linked to better outcomes and lower recurrence after ablation.

None of these are a substitute for medical treatment. They form the foundation that the rest of the treatment plan sits on, and they are the part of the plan most under the patient's daily control.

Where Standard Care Falls Short

The standard AFib toolbox is real and useful. It controls the rate, manages the rhythm, and reduces stroke risk. For many patients, that is enough to live a full life. For others, it is not.

Each of the standard options is organized around the symptom rather than the cause. Rate control slows how fast the heart responds. Rhythm control tries to hold the rhythm in place while a drug is in the system. Anticoagulation manages the consequences of clot formation. Ablation scars tissue to block misfiring signals. None of them are designed to address the inflammation along the nerves that increasingly appears in the underlying picture of AFib.

That gap is why a growing number of patients ask whether there is something working on a different layer.

A New Frontier: Kaorta

Kaorta® is the only U.S. based patented cell therapy protocol developed for atrial fibrillation and congestive heart failure. AFib and CHF share a root driver: inflammation along the nerves that tell the heart when to beat. Kaorta® is built around that layer of the condition.

The approach started in our neuropathy practice, where the same cells were used to support recovery around inflamed nerves in the brain. After nine years of developing the PVC method, we recognized the same kind of inflammation behind AFib and CHF, sitting on the nerves that signal the heart. The first AFib patient was treated in 2023 and has lived a normal life since.

A treatment cycle begins with tissue donated by the patient or a related donor and collected by a plastic surgeon. The harvest is developed into PVC (perivascular) cells through a patented process carried out inside an FDA registered laboratory, with the patent and the laboratory held by separate entities. On treatment day, the cells are delivered through a single IV infusion in a clinic setting. The patient sits in a chair, the bag drips in, and the patient goes home the same day.

Several points set Kaorta® apart from the standard AFib playbook:

• Built for the cause, not the symptom. The protocol is designed to work on the inflammation along the nerves that drives AFib and CHF, rather than on the rhythm or the rate that follows from it.
• A single IV infusion. Treatment is delivered in one outpatient visit. The patient goes home the same day.
• A live cell product with documented counts. Each unit is released with recorded total nucleated cells, total cells, and live cell viability, typically reported between 95 and 100%.
• Inside the FDA framework. The therapy follows rigorous protocols and complies with FDA guidelines outlined in 21 CFR 1271.10, which define oversight under section 361 of the PHS Act and 21 CFR Part 1271.
• Designed alongside cardiology care. Kaorta® is not a replacement for a cardiologist's plan. It is a different layer of the same condition, intended to sit alongside the standard tools rather than displace them.

The PVC cells help the body reduce the inflammation along the nerves that signal the heart. As that inflammation comes down, the nerves have room to recover and the rhythm has a chance to steady.

Sources

• Joglar, J. A., et al. "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation." Circulation, 2024.
• Haïssaguerre, M., et al. "Spontaneous Initiation of Atrial Fibrillation by Ectopic Beats Originating in the Pulmonary Veins." New England Journal of Medicine, 1998.
• Cox, J. L., et al. "The Surgical Treatment of Atrial Fibrillation. III. Development of a Definitive Surgical Procedure." Journal of Thoracic and Cardiovascular Surgery, 1991.
• Lown, B., Amarasingham, R., Neuman, J. "New Method for Terminating Cardiac Arrhythmias: Use of Synchronized Capacitor Discharge." JAMA, 1962.
• Lip, G. Y., et al. "Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor Based Approach: The Euro Heart Survey on Atrial Fibrillation." Chest, 2010.
• U.S. Food and Drug Administration. "21 CFR Part 1271: Human Cells, Tissues, and Cellular and Tissue Based Products."